Get Live Data

Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Curevac N V Ord Share Price
  4. Curevac N V Ord Share Regulatory News

Pin to quick picksCurevac N V Ord Regulatory News (0A9E)

Curevac N V Ord Information

Share Price Information for Curevac N V Ord (0A9E)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.981
Bid: 3.782
Ask: 4.18
Change: -0.124 (-3.02%)
Spread: 0.398 (10.524%)
Open: 4.124
High: 4.261
Low: 3.88
Prev. Close: 4.105
0A9E Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

12
Date   Source Headline
30th Mar 202212:01 pmEQSCureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
1st Mar 202212:01 pmEQSCureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
10th Feb 202212:01 pmEQSCureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
17th Jan 202212:01 pmEQSCureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
18th Nov 20219:11 pmEQSCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
18th Nov 20219:11 pmEQSCureVac veröffentlicht Finanzergebnisse für das dritte Quartal sowie die ersten neun Monate 2021 und informiert über das laufende Geschäft
18th Nov 202110:43 amEQSCureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
18th Nov 202110:43 amEQSCureVac veröffentlicht in „Nature' präklinische Daten des COVID-19-Kandidaten der zweiten Generation, CV2CoV, die vergleichbaren Antikörperspiegel wie bei lizenziertem mRNA-Impfstoff nachweisen
10th Nov 202112:01 pmEQSCureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
10th Nov 202112:01 pmEQSCureVac präsentiert Daten auf SITC Konferenz aus Phase-1-Studie von Onkologie-Kandidat CV8102, die systemische Immunantwort zeigen
12th Oct 202112:03 pmEQSCureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
12th Oct 202112:03 pmEQSCureVac verlagert Fokus der COVID-19-Impfstoffentwicklung auf mRNA-Technologie der zweiten Generation
14th Sep 202112:20 pmRNSCureVac verschlankt europäisches Netzwerk zur mRNA-Produktherstellung
14th Sep 202112:20 pmRNSCureVac Streamlines European Network for mRNA Product Manufacturing
31st Aug 202112:00 pmEQSCureVacs Phase 2b/3-Studiendaten für CVnCoV auf Pre-Print-Server The Lancet veröffentlicht
31st Aug 202112:00 pmEQSCureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
30th Aug 202112:00 pmEQSCureVac-Studie: Präklinische Daten zeigen deutliche Verminderung von Leberfibrose mit mRNA-Therapeutikum
30th Aug 202112:00 pmEQSCureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
16th Aug 202112:11 pmEQSCureVac veröffentlicht Finanzergebnisse des zweiten Quartals und ersten Halbjahres 2021 und informiert über seine Geschäftsentwicklung
16th Aug 202112:11 pmEQSCureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
16th Aug 202112:00 pmEQSCureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
16th Aug 202112:00 pmEQSCureVac : mRNA-basierter COVID-19-Impfstoffkandidat der zweiten Generation, CV2CoV, zeigt verbesserte Immunantwort und Schutzwirkung in präklinischer Studie
30th Jun 20219:30 pmEQSCureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
30th Jun 20219:30 pmEQSCureVacs Daten der finalen Analyse der Phase 2b/3-Studie für CVnCoV, den Impfstoffkandidaten der ersten Generation, zeigen Schutzwirkung in Altersgruppe von 18 bis 60 Jahren
30th Jun 202112:00 pmEQSCureVac gibt Ernennung von Dr. Malte Greune zum Chief Operating Officer und den Funktionswechsel von Dr. Florian von der Mülbe zur beschleunigten Weiterentwicklung des The RNA Printer(R) bekannt
30th Jun 202112:00 pmEQSCureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
24th Jun 20219:15 pmEQSCureVac Announces Voting Results of General Meeting
24th Jun 20219:15 pmEQSCureVac Announces Voting Results of General Meeting (English only)
23rd Jun 202112:30 pmEQSCureVac Provides Supervisory Board Update
23rd Jun 202112:30 pmEQSCureVac gibt personelle Änderungen im Aufsichtsrat bekannt
16th Jun 20219:42 pmEQSCureVac gibt Status-Update zur Phase 2b/3-Studie für Impfstoffkandidat der ersten Generation CVnCoV bekannt
16th Jun 20219:42 pmEQSCureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
2nd Jun 202112:00 pmEQSCureVac Appoints Klaus Edvardsen as Chief Development Officer
2nd Jun 202112:00 pmEQSCureVac ernennt Klaus Edvardsen zum Chief Development Officer
28th May 20219:30 pmEQSCureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
28th May 20219:30 pmEQSCureVacs Impfstoffkandidat der ersten Generation, CVnCoV, setzt nach DSMB-Empfehlung in Phase 2b/3 Wirksamkeitsnachweis in variantengeprägtem Umfeld fort
26th May 202112:00 pmEQSCureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
26th May 202112:00 pmEQSCureVac veröffentlicht Finanzergebnisse des ersten Quartals 2021 und informiert über seine Geschäftsentwicklung
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.